Deguelin Attenuates Reperfusion Injury and Improves Outcome after Orthotopic Lung Transplantation in the Rat by Paulus, Patrick et al.
Deguelin Attenuates Reperfusion Injury and Improves
Outcome after Orthotopic Lung Transplantation in the
Rat
Patrick Paulus
1*, Pia Ockelmann
1, Sabine Tacke
2, Nora Karnowski
3, Peter Ellinghaus
3, Bertram Scheller
1,
Johannes Holfeld
4, Anja Urbschat
5, Kai Zacharowski
1
1Clinic of Anesthesiology, Intensive Care Medicine and Pain Therapy, Goethe-University Hospital Frankfurt, Frankfurt am Main, Germany, 2Department of Veterinary
Clinical Sciences, Clinic for Small Animals Surgery, Justus-Liebig University, Giessen, Germany, 3Clinical Pharmacology, Global Biomarker, Bayer Pharma AG, Wuppertal,
Germany, 4Clinic of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria, 5Clinic of Urology, Goethe-University Hospital Frankfurt am Main, Germany
Abstract
The main goal of adequate organ preservation is to avoid further cellular metabolism during the phase of ischemia.
However, modern preservation solutions do rarely achieve this target. In donor organs hypoxia and ischemia induce a broad
spectrum of pathologic molecular mechanisms favoring primary graft dysfunction (PGD) after transplantation. Increased
hypoxia-induced transcriptional activity leads to increased vascular permeability which in turn is the soil of a reperfusion
edema and the enhancement of a pro-inflammatory response in the graft after reperfusion. We hypothesize that inhibition
of the respiration chain in mitochondria and thus inhibition of the hypoxia induced mechanisms might reduce reperfusion
edema and consecutively improve survival in vivo. In this study we demonstrate that the rotenoid Deguelin reduces the
expression of hypoxia induced target genes, and especially VEGF-A, dose-dependently in hypoxic human lung derived cells.
Furthermore, Deguelin significantly suppresses the mRNA expression of the HIF target genes VEGF-A, the pro-inflammatory
CXCR4 and ICAM-1 in ischemic lungs vs. control lungs. After lung transplantation, the VEGF-A induced reperfusion-edema is
significantly lower in Deguelin-treated animals than in controls. Deguelin-treated rats exhibit a significantly increased
survival-rate after transplantation. Additionally, a downregulation of the pro-inflammatory molecules ICAM-1 and CXCR4
and an increase in the recruitment of immunomodulatory monocytes (CD163+ and CD68+) to the transplanted organ
involving the IL4 pathway was observed. Therefore, we conclude that ischemic periods preceding reperfusion are mainly
responsible for the increased vascular permeability via upregulation of VEGF. Together with this, the resulting endothelial
dysfunction also enhances inflammation and consequently lung dysfunction. Deguelin significantly decreases a VEGF-A
induced reperfusion edema, induces the recruitment of immunomodulatory monocytes and thus improves organ function
and survival after lung transplantation by interfering with hypoxia induced signaling.
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Introduction
Lung transplantation is, despite the highest mortality among all
solid organ transplants, the only therapeutic option in patients
with end-stage pulmonary disease [1]. The fragility and the poor
tolerance against ischemia of this organ is responsible for the fact
that only 20% of the candidate lungs are currently being
transplanted [2]. Today, primary graft dysfunction (PGD)
represents the most common acute complication during the first
30 days after lung transplantation [1,3]. PGD mainly develops on
the soil of an ischemia-reperfusion (IR) reaction that is character-
ized by an overshooting inflammatory response, culminating in
tissue edema and consecutive graft failure [4,5].
Despite downregulation of the cellular metabolism by modern
preservation methods (i.e. preservation solutions, hypothermia
etc.), hypoxia- induced gene transcription is not completely
blunted. However, the complete blockade of the cellular metab-
olism for the time of ischemia might be of benefit. First, due to the
loss of oxygen consumption, no metabolites are produced, that
might have an adverse effect on cellular viability. Second, upon
inhibition of cellular respiration, the intracellular oxygen concen-
tration remains normal under ischemia, and thus oxygen is
available for hydroxylation of the transcription factor Hypoxia
Inducible Factor (HIF)-1, thus resulting in its decreased transcrip-
tional activity [6,7,8].
HIF-1 occupies a central and critical role, involving a large
number of genes [9]. Among these genes, especially Vascular
Endothelial Growth Factor (VEGF) and genes that regulate cell
adhesion to the endothelium such as Inter-Cellular Adhesion Molecule
(ICAM)-1 are activated within minutes by HIF-1
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permeability about 50.000 times stronger than histamine, by
enhancing the break-down of the endothelial barrier function and
inducing the formation of interendothelial gaps [16]. This in turn
leads to an increased tissue edema ending up in organ failure
[14,17,18,19,20,21,22,23]. Together with ICAM-1, VEGF is
highly chemotactic for inflammatory cells like monocytes [24,25].
Clinically relevant effects of hypoxia induced pathomechanisms
are observed in high-altitude mountaineers, where low oxygen
tension is highly correlated with lung and brain edema, as well as
systemic inflammatory response syndrome [26,27,28,29]. Hypoxia
thus triggers inflammation, and on the other hand, inflammation
itself causes local hypoxia, combined with activation of the
coagulation system [19,30], leading to a vicious circle as seen in
acute lung injury [31,32].
After restoration of the normal blood flow (reperfusion), the
resulting increased concentration of pulmonary VEGF leads to an
increased vascular permeability resulting in early post transplan-
tation dysfunction [33,34,35,36,37].
However, the main functions of the hypoxia induced genes are
meant ‘‘self-protective’’ by preventing organ damage (i.e. increase
of hemoglobin, increase of micro-vessel density through neo-
angiogenesis, increase of glycolysis to ensure cellular metabolism).
Unfortunately, at least in endothelium-rich tissues, these effects
seem to have a negative impact on the outcome after ischemic
events i.e. transplantation. It has been shown that these negative
effects are mainly triggered by HIF-1 and thus correlate with
primary graft failure [14,15,22,38]. A dual blockade of the
respiration chain and the hypoxia induced gene expression might
therefore be of benefit in lung transplantation.
The rotenoid Deguelin is able to provide this dual inhibition.
Deguelin acts as a mitochondrial inhibitor of the respiration chain
via inhibition of the mitochondrial NADH dehydrogenase/
complex I [39]. The resulting reduced oxygen consumption leads
to increased HIF-1 hydroxylation and thus inhibition of its
transcriptional activity [7]. Therefore, a blockade of the delete-
rious effects of HIF-1 during lung transplantation might be
beneficial to prevent PGD and improve short-term survival by
reducing tissue edema.
Results
Deguelin Gavage is Well Tolerated
All animals received two daily gavages of Deguelin intra-
gastrically at 4 mg/kg bodyweight for 3 days. All animals treated
with Deguelin or solvent significantly gained weight during the
trial (297.869.805 g and 335.662.064 g vs. 257.164.389 g,
P=0.0009, P,0.0001 resp.). However, animals receiving only
solvent, were significantly heavier compared to the Deguelin
treated animals (335.662.064 vs. 297.869.805, {P=0.0196). No
deleterious side effects were observed in all groups (Fig. 1).
Deguelin Effectively Blocks HIF-1 during Hypoxia in vitro
Deguelin effectively suppressed HIF-1 protein after 6 hours
hypoxia in vitro at a concentration of 100 nM in human
microvascular endothelial cells (HMECs) as well as in human
lung epithelial derived cells (NCI-H460 and HTB-177). DMSO
(solvent) with hypoxia and hypoxia (HOX) alone stabilized HIF-
1(Fig. 2A). Deguelin effectively inhibits the hypoxia-induced
expression of HIF target genes in a concentration dependent
manner. Carbonic anhydrase IX (CAIX), vascular endothelial
growth factor (VEGF)-A, lysyl oxidase (LOX), angiopoietin-related
protein 4 (ANGPTL4), egl nine homolog 3 (EGLN3) and
adrenomedullin (ADM) mRNA expression is significantly down-
regulated in hypoxic cells (HOX) upon treatment (Fig. 2B).
EGLN2, a HIF prolyl hydroxylase that is not a HIF target gene
serves as negative control, to show that Deguelin is not a general
transcription inhibitor.
Deguelin Effectively Blocks HIF-1 during Hypoxia in vivo
To test whether Deguelin has a sufficient in vivo activity,
treatment was initiated 3 days prior to sacrification at 4 mg/kg
BW twice/day. On day 4 the animals were killed and the lungs
were excised and stored at 37uC for 1 h, simulating warm
ischemia (w.i.). Sham lungs were immediately snap-frozen
without ischemia (Fig. 3A). The readout was performed on
these samples by measuring HIF-1 regulated genes using RT-
PCR. Basal mRNA expression under normoxia (sham) was
detectable for VEGF-A (100.0612.28), CXCR4 (100.0619.97)
and ICAM-1 (99.9612.28). Under warm ischemia, VEGF-A
(217.8644.98; P=0.0338) and CXCR4 (272.0660.82;
P=0.0291) were significantly upregulated vs. sham, whereas
the changes in ICAM-1 (136.5618.93; n.s.) gene expression
were not significant. Deguelin treatment (w.i.D.) significantly
blunted VEGF-A (68.8617.90; P=0.0042), CXCR4
(11.965.53; P=0.0003) and ICAM-1 (42.467.36; P,0.0001)
mRNA levels compared to warm ischemia. The gene expression
of the corresponding negative control b-Actin (ACTB) remained
unchanged (Fig. 3B). These results indicate that Deguelin
potently interferes with the hypoxia induced gene expression
(Fig. 2B). Especially VEGF-A, which regulates vascular perme-
ability, and ICAM-1 as well as CXCR4, two genes regulating
Figure 1. Deguelin gavage is well tolerated. Bodyweight is
determined before and after Deguelin treatment. The gain in body-
weight is a sign for good tolerance of the substance. The graph
represents the increases in bodyweight vs. weight at begin of the
experiment. Columns and error bars represent means 6 SEM. {,P ,0.02;
***, P#0.0009; one-way ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g001
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39265Figure 2. Deguelin effectively inhibits HIF-1 and its reporter genes during hypoxia in vitro. Human lung epithelial derived and endothelial
cells are incubated for 6 hours under hypoxia. Different concentrations of Deguelin are tested to determine a concentration dependent inhibition of
HIF-1 induced genes. (A) Western blot analysis of lung derived epithelial cells (NCI-H460 and HTB-177) and human microvascular endothelial cells
(HMEC) revealed the concentration dependent suppression of HIF-1 by Deguelin. Beta-Actin (ACTB) serves as internal negative control. (B) Graphs
representing mRNA expression profiles of HIF-1 regulated genes: concentration dependent inhibition HIF-1 induced target genes. EGLN2 expression
serves as internal negative control. NOX=normoxia, HOX=hypoxia. Measurements were performed in triplicate. Columns and error bars represent
means 6 SEM. * indicates significance level vs. HOX; *, P,0.05; **, P#0.01; ***, P,0.0005; one-way ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g002
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suppressed by systemic Deguelin treatment.
Deguelin Prevents from Structural Changes and Cellular
Edema in Ischemic Lungs
From the organs stored at 37uC for 1 h, samples were
collected and histology was performed. All sections were stained
with H&E and pictures with 106 and 406 magnification were
taken. To quantify cellular edema and structural pulmonary
changes, the area occupied by tissue (positive H&E staining) was
determined planimetrically. For this purpose, 3 randomly taken
pictures from each slice were analyzed (Fig. 4A, blue). The
increase in cellular edema and structural changes directly
correlate with the increase in area occupied by lung tissue per
section. Lungs from animals that received Deguelin (w.i.D.)
prior to ischemia (36.562.88% tissue/area), displayed signifi-
cantly reduced cellular edema and structural changes than those
from sham (50.561.34% tissue/area) or with warm ischemia
(w.i.) (55.262.73% tissue/area) groups (Fig. 4B). In animals
receiving Deguelin (w.i.D.), the microstructure was preserved.
These results indicate that hypoxia/ischemia mediate the
development of acute tissue edema.
Deguelin Treatment Reduces Reperfusion Edema by
Suppression of VEGF-A Protein in Lung Grafts and
Improves Short-term Survival after Orthotopic Lung
Transplantation
To test the hypothesis whether Deguelin might reduce tissue
edema in vivo via modulation of the VEGF-A pathway, we
performed transplantation experiments. For this purpose we
transplanted the left lung from either pre-treated donors to pre-
treated recipients (Deguelin) or the left lung from non-treated
donors to non-treated recipients (control). Analysis of the
transplanted organs revealed that lungs from animals, which
were treated with Deguelin, had significantly lower levels of
VEGF-A mRNA and protein when compared to untreated
subjects (Fig. 5A).
A small part of the transplanted left lung was used to determine
the wet-to-dry ratio, directly reflecting the extent of reperfusion
edema in the lung tissue. Animals, which received Deguelin, had
significantly less tissue water and thus less edema compared to
lungs that did not receive any treatment (Fig. 5B left graph).
Together with these findings, animals that had lower post-
transplantation-edema also had a significant better survival rate.
100% of the Deguelin treated animals (Deguelin) survived until the
end of the observation period of 48 h, whereas controls only
showed a mean survival of 17.4269.672 hours (P=0.0101; Fig. 5B
right graph). The better survival therefore directly correlates with
the blunted VEGF-A expression, showing the direct correlation of
VEGF-A and the development of tissue edema and organ
dysfunction.
In corresponding micrographs, lungs that have a high degree of
edema show similar structural changes compared to lungs from the
preliminary experiment (Fig. 5C) that underwent warm ischemia,
without administration of Deguelin. These data suggest, that
hypoxia directly induces reperfusion edema via the upregulation of
VEGF-A expression.
Deguelin Treatment Diminishes the Pro-inflammatory
Tissue Response and Stimulates Immunomodulation via
Recruitment of Anti-inflammatory M2 Macrophages
Deguelin protects from acute inflammation by downregulating
pro-inflammatory peptides such as ICAM-1 and CXCR4. In
Deguelin treated animals, tissue expression of the pro-inflamma-
tory genes, directly regulated by hypoxia, is blunted as a result of
the treatment. ICAM-1 (26.565.3 vs. 127.8649.6; P=0.0188)
and CXCR4 (58.968.7 vs. 107.7620.6; P=0.0274) gene
expression is significantly downregulated in Deguelin treated
animals vs. controls. In contrast, tissue mRNA expression of
markers related to the recruitment of anti-inflammatory macro-
phage populations such as IL4 (153.1614.5 vs. 100.0617.2;
P=0.0357), mannose receptor C type 1 (MRC-1) (320.5696.6 vs.
100.0624.9; P=0.044), CCL2 (290.0635.7 vs. 99.9622.4;
P=0.0001) and CD 163 (1262.06266.6 vs. 100.0618.5;
P=0.0008) is significantly upregulated in Deguelin treated animals
vs. controls. These findings indicate that in this in vivo model, the
recruitment of M2 macrophage populations is CCL2, IL4 and
MRC-1 dependent (Fig. 6). Concerning IL10, our data show a
downregulation in Deguelin treated animals vs. controls
(36.1868.323 vs. 100.063.801; P,0.0001).
Besides, Deguelin also has immunomodulatory effects on the
donor lung by favoring the recruitment of anti-inflammatory
macrophages (CD 163+) involving the CCL2/MRC-1/IL4
pathway. In corresponding micrographs, the amount of CD
163+ cells is significantly higher in animals that have been treated
with Deguelin vs. controls (36.263.7 vs. 8.763.1; P,0.0001). This
directly correlates with the better outcome of these animals. A CD
68 staining reveals that mature macrophages are mainly partic-
ipating in this anti-inflammatory and HIF-1 inhibitory effect. In
Deguelin treated animals the amount of CD 68+ cells is
significantly higher than in non-treated animals (37.865.9 vs.
8.562.2; P,0.0001) and thus correlates directly with the amount
of CD163+ cells. However, in a pan-macrophage/dendritic cell
staining (RM-4), the total macrophage count is significantly higher
in untreated than in Deguelin treated animals (67.461.9 vs.
34.062.3; P,0.0001). Furthermore, the amount of RM-4
positively stained macrophages in the Deguelin group corresponds
to the amount of CD-163+ cells from the same group (Fig. 7).
Interestingly, it seems that the CD 68+ and CD 163+ cells are
attracted via CCL2/MRC-1/IL4 rather than IL10 or ICAM-1
signals. ICAM-1 immunostaining shows that its expression is
blunted in Deguelin treated animals (9.862.7 vs. 63.266.3;
P,0.0001) and thus correlates with tissue mRNA ICAM-1
expression (Fig. 6, 7).
IL6 Protein Downregulation and Interferon (IFN) c Protein
Upregulation is Co-associated with Adverse Outcome
IL6 and IFNc are known to play an important role in
inflammatory reactions especially in accordance to rejection
reactions. As the recruitment of M2 macrophages also requires
to some extent a pro-inflammatory reaction, we aimed to test
whether IL6 or IFNc might be regulated in our experimental
setting. Therefore we performed ELISA on serum samples derived
from sham, Deguelin and Perfadex-treated (control) rats. Inter-
estingly, animals that have been treated with Perfadex only, have
significantly lower levels of serum IL6 as seen in Deguelin or sham
animals (81.5614.3 pg/ml vs. 200.0632.8 pg/ml
resp.178.9622.0 pg/ml; P,0.004). Consistent with this, the
serum protein expression of IFNc is significantly upregulated in
controls vs. Deguelin treated animals (6.160.5 pg/ml vs.
3.960.3 pg/ml; P=0.0025). These data show that both IL6 and
IFNc might play an important role in orchestrating these
inflammatory reactions and showing that a lack of IL6 and an
overexpression of IFNc are co-associated with the M1 or pro-
inflammatory macrophage phenotype (Fig. 8).
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39265Figure 3. Deguelin effectively inhibits pro-edema and pro-inflammatory genes during hypoxia in vivo. Lungs from animals pretreated
with or without Deguelin are explanted. After 1 hour incubation at 37uC, simulating warm ischemia, the ischemic lungs are processed for further
analysis. (A) Scheme representing the ischemia experiment. (B) Gene expression of VEGF-A, CXCR4 and ICAM-1 in ischemic lungs treated with or
without Deguelin. Beta actin served as negative control. Groups are compared to native Lungs (sham). Sham = native lungs without ischemia, w.i. =
ischemic lungs without treatment, w.i.D = ischemic lungs with Deguelin treatment. Measurements were performed in triplicate. Columns and error
bars represent means 6 SEM. * indicates significance level vs. sham, { indicates significance level vs. w.i.; *, P,0.05; ***, P,0.0005; {{,P ,0.005; {{{,
P,0.0005; one-way ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39265Figure 4. Deguelin prevents from ischemia induced edema and loss of lung microstructure. From the explantation experiment,
micrographs are analyzed to detect structural edema as sign for organ damage. (A) Representative H&E micrographs (purple) from native lungs
(sham), ischemic lungs without treatment (w.i.) and ischemic lungs with deguelin treatment (w.i.D). The blue graphs represent planimetric evaluation
of the H&E stains to evaluate the area/field occupied by tissue as measurement for edema. Magnifications used: 106 and 406. Bar in the 106
magnified micrographs represent 100 mm and in the 406magnified micrographs represent 50 mm. From each H&E stain representing always one
animal, 3 different areas were photographed and evaluated. (B) Graph representing the evaluation of the planimetric measurements. Columns and
error bars represent means 6 SEM. * indicates significance level vs. sham, { indicates significance level vs. w.i.; ***, P,0.0005; {{{,P ,0.0001; one-way
ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39265Figure 5. VEGF-A activity correlates with edema formation. The transplantation experiments compromise two groups, one control (perfadex
only) and one Deguelin treated group. Animals receiving Deguelin (donor and recipient) are pretreated 3 days prior transplantation and treatment is
kept upright in the recipients until the end of the experiment after 48 hours after transplantation. (A) Graphs and representative western blot images
representing tissue VEGF-A mRNA and protein levels after transplantation and reperfusion. Animals that received Deguelin are compared vs. controls.
(B) Right graph representing the wet-to-dry ratio evaluating the extent of tissue edema. Left graph representing the mean survival expressed in hours
of both groups (controls vs. animals that received Deguelin). (C) Corresponding micrographs (106magnification, H&E) show microstructural changes
that occur after reperfusion. Calibration bar represents 100 mm. Columns and error bars represent means 6 SEM. * indicates significance level vs.
control. ***, P,0.0005; one-way ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g005
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39265Figure 6. Hypoxia and reperfusion induce inflammatory gene expression. 48 hours after transplantation, the graft is analyzed for hypoxia
induced pro-inflammatory pathways via RT-PCR. Graphs representing the mRNA expression of hypoxia induced inflammatory mechanisms (ICAM-1
and CXCR4) and mRNA expression of markers of anti-inflammatory monocytic cell recruitment in lungs at the end of the reperfusion phase. Columns
and error bars represent means 6 SEM. { indicates significance level vs. controls; * indicates significance levels vs. sham; one-way ANOVA and
unpaired t test.
doi:10.1371/journal.pone.0039265.g006
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39265Figure 7. Anti-inflammatory macrophages are recruited to Deguelin treated lungs. Figure representing micrographs of cellular invasion
into transplanted lungs at the end of the reperfusion phase. The left micrographs represent control animals and the right micrographs represent
animals that received Deguelin treatment. From top to bottom, micrographs represent DAB immunostainings from RM-4 (pan-macrophage), ICAM-1,
CXCR4, CD68 and CD163. Magnification was set at 406and 1006for pictures in picture. CXCR4 micrographs are represented in 206magnification.
Calibration bar represents 50 mm (406). The graphs represent the statistical evaluation of each cell type. The upper graph represents a total
macrophage count (RM-4+ cells), followed by ICAM-1+ cell count and CXCR4staining. The last two graphs represent CD68+ cell count, and finally a CD
163+ cell count. Arrowheads mark positively stained cells. Evaluation for CXCR4 is performed by calculating the ratio between positively and
negatively stained amount of cells to avoid bias from alveoli that contain no cells. Arrowheads mark positively stained cells. Columns and error bars
represent means 6 SEM. * indicates significance level vs. control. ***, P,0.0001; one-way ANOVA and unpaired t test.
doi:10.1371/journal.pone.0039265.g007
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Today, the number of patients on the waiting lists for organ
transplantation is steadily increasing; in contrast, the number of
available organs is not. This leads to the fact that currently organs
are considered for transplantation even when potentially subjected
to longer ischemia periods or poor hemodynamics of the donor.
Some years ago, they probably would have been rejected [40].
Given these circumstances, pharmacologic protection of the
available organs is of increasing interest. Ischemia and reperfusion
(IR) injury to organs represents one of the most common clinical
problems in transplantation medicine. IR may lead to primary or
secondary organ failure after restoration of the blood flow
[41,42,43]. The theory that hypoxia triggers inflammation is not
new. There is sufficient evidence that hypoxia leads to activation of
several deleterious pathways like the occurrence of edema due to
enhanced vascular leakage and accumulation of inflammatory cells
in organs, increasing the risk of early and late graft rejection after
transplantation [27]. Hypoxia or ischemia are known triggers of a
vicious circle, enhancing inflammation and organ damage.
Simplified, the paradigm - tissue hypoxia leads to inflammation,
tissue inflammation leads to hypoxia- can be applied [44].
During hypoxia or ischemia, HIF-1 is mainly responsible for the
initiation of gene transcription in many lung diseases like gut-
induced lung injury following IR, hypoxic pulmonary hyperten-
sion, COPD and fibrous airway remodeling [45,46,47,48].
Hypoxia stabilizes HIF-1 which in turn directly and quickly
upregulates target gene’s expression within minutes [49,50,51,52].
Usually, the maximum transcription rate culminates at 2 hours of
hypoxia. In the present study, however, we could demonstrate that
HIF-1 induces transcription in ischemic lung tissue already much
earlier (within 1 hour), however with lower efficacy. The reason for
this quick response upon hypoxia might be explained by the fact
that hypoxic organs and cells have to react immediately to prevent
damage and ensure survival of the organism. Therefore we
suppose that HIF-1 has two major actions, a deleterious fast and
pro-edematous one, and a longer lasting one, namely angiogenesis
and endothelial proliferation [17]. In transplantation medicine,
VEGF has been shown to exert pro-inflammatory and pro-
apoptotic actions during the early phase of reperfusion [53]. Our
own data concerning patients who underwent lung or heart
transplantation could correlate increased HIF-1 binding activity
and high VEGF-A levels with more pronounced edema and
rejection rates [22,23,37]. Therefore these findings led to the
hypothesis that the inhibition of VEGF-A pathways, as well as
other hypoxia triggered pro-inflammatory genes such as ICAM-1
and CXCR4 could reduce early complications such as edema-
caused PGD after lung transplantation. Several recent publications
also describe protective effects of the latter genes. Namely the work
by Jiang et al. demonstrated that a therapeutic enhancement of the
vascular integrity via HIF-1 activation during acute rejection
promotes tracheal graft health and prevents from chronic rejection
[54]. This work stands in direct contrast to the work of Krebs et al.
who demonstrated that VEGF is responsible for the occurrence of
bronchiolitis obliterans [55]. These data indicate that the sum of
the hypoxia induced effects might be protective. One possible
explanation might be that the work by Jiang et al. does not include
short-term survival results reflecting early complications. As the
trachea is not participating in the gas exchange, animals might
show early inflammation, but they will not die of it, as both lungs
are still functional and gas exchange remains unchanged. To test
our hypothesis that the summative effects of hypoxia negatively
influence the graft fate during the early reperfusion phase by
increasing tissue edema and inflammation, we used the model of
orthotopic lung transplantation in the rat. This model has the
advantage that a read out of early complications by providing
short term survival data is possible. In the present work, we could
demonstrate that the summative effect of hypoxia induced gene
expression is deleterious. We could show for the first time that
solely 1 hour of hypoxia leads to an increase of pro-edematous
VEGF-A mRNA expression and in turn leading to an edematous
tissue alteration as shown in figure 4. Transplanted and reperfused
lungs without Deguelin treatment had a high water content as
depicted in the wet-to-dry ratio (Fig. 5B). Together with this, the
survival was significantly increased in the Deguelin group,
underlining the beneficial effect of HIF-1 Inhibition in vivo. The
Figure 8. Low Serum IL6 and high Interferon (IFN) c levels are
associated with adverse outcome. Fig. 8 shows ELISA analyses of
serum samples from sham, Deguelin and Perfadex (controls) treated
animals from the transplantation experiment. IL6 is significantly blunted
in controls vs. sham or Deguelin treated animals. The pro-inflammatory
IFN c is upregulated in controls vs. Deguelin or sham animals. Columns
and error bars represent means 6 SEM. { indicates significance level vs.
controls; * indicates significance levels vs. sham; one-way ANOVA and
unpaired t test.
doi:10.1371/journal.pone.0039265.g008
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properties might rather directly result from inhibition of the HIF-1
pathway than from interference with the Pi3K/Akt pathway,
which is not addressed by the concentration of deguelin used in
this model (Fig. 9). Our data show for the first time that treatment
with Deguelin significantly reduces hypoxia induced deleterious
effects in lung grafts and thereby significantly lowers reperfusion
edema and improves survival. These results indicate that systemic
perioperative inhibition of the respiratory chain in mitochondria in
donor organs might be a beneficial therapeutic option. It was
shown recently that ICAM-1 and CXCR4 are involved in lung
injury via recruitment of inflammatory cells [56,57]. We could
now demonstrate that Deguelin application in vitro and in vivo leads
to a consecutive downregulation of ICAM-1 and CXCR4. This
attenuation consequently leads to less inflammation in the grafts.
When looking at the micrographs, we found however that
Deguelin treatment leads to occupation of the alveolar spaces by
monocytic cells. This however appears not logical, as the lung
inflammation markers ICAM-1 and CXCR4 were downregulated.
Immunohistochemical staining revealed that these monocytic cells
highly expressed the surface markers CD 163, meaning that these
monocytes are anti-inflammatory macrophages. The marker CD
68, which represents mature macrophages, is poorly expressed in
healthy lungs, however in the transplanted lung CD 68 is
upregulated indicating that the anti-inflammatory macrophages
are fully differentiated. Whether these macrophages are recruited
as precursor cells or whether these cells are host derived remains
unclear at this moment. The RM-4 staining (pan-macrophage
marker) shows that transplanted lungs have in total fewer
monocytic cells. Interestingly, nearly 100% of these cells are
anti-inflammatory. As we used an allo-isogenic model, a mild
immunologic reaction is accepted, simulating a good cross-match.
Interestingly, IL10, a potent chemoattractant for anti-inflamma-
tory macrophages is downregulated in Deguelin-treated animals.
However, a downregulation of the anti-inflammatory cytokine
IL10 is not contradictory. First, IL10 is mainly produced by
antigen presenting cells (APCs). Immunocytochemistry showed
that the infiltrating immune cells in the HIF-1 inhibitor-treated
group are mainly anti-inflammatory. Therefore few APCs are
recruited to the lung, resulting in a downregulated IL10
expression. Secondly, recent works demonstrated that IL10 must
already be upregulated before the event to act as anti-inflamma-
tory agent. Should it be upregulated after the inflammatory event,
it has a pro-inflammatory effect [58]. Thirdly, IL4 is known to
downregulate IL10 expression [59]. As IL4 is upregulated in
Deguelin treated rats, the downregulation of IL10 is plausible. On
the other hand, serum analysis of IL6 and IFNc revealed, that
control animals have significantly lower levels of IL6 and
significantly higher levels of IFNc. It is known that IL6 is not
only a simple pro-inflammatory cytokine. Together with IL4, IL6
induces M2 polarization of macrophages, which reflects our
findings [60]. The rather high level of IL6 in the sham group is
plausible, as the thoracotomy leads to a rather large wound, which
is known to upregulate IL6. Higher IL6 levels in Deguelin treated
animals thus directly correlate with the better outcome. The low
IL6 levels in the controls might also reflect the effect of IFNc or
might be explained by a different IL6 kinetics in this group.
Comparatively IFNc, that is known to inhibit M2 polarization in
vivo, is upregulated in control animals, which show low levels of
M2 macrophages [61]. Thus, this cytokine profile is plausible and
reflects the pathways involved in M2 differentiation in this animal
model. We think that for the initiation of a M2 polarization, some
extent of inflammation must precede this reaction. Once
macrophages are recruited to the site of inflammation, IL4,
MRC-1 and CCL2 initiate M2 polarization. In the case of the
controls, the initial IL6 upregulation is missing and thus, M2
differentiation is missing. Together with this, IL10, CXCR4 and
ICAM-1 upregulation is leading to an overshooting inflammatory
response. However, the exact mechanisms underlying this
complex reaction remain unclear. We think it is rather a
consequence of the cells infiltrating the grafts and the following
specific reactions initiated by target-oriented cytokines. Therefore
Deguelin is not likely to directly stimulate IL6, CCL2 or MRC-1.
Taken together, our data clearly indicate that in the model of
orthotopic lung transplantation, a systemic treatment with
Deguelin prior to transplantation is beneficial and reduces early
complications such as PGD. The suppression of hypoxia induced
pathomechanisms leads to an attenuated VEGF-A activity and
therefore significantly reduces reperfusion edema. Deguelin
treatment also prevents from pro-inflammatory phenotypes by
suppressing ICAM-1 and CXCR4 expression. The exact mech-
anisms, by which Deguelin influences the CCL2, MRC-1 and IL4
signals are yet unknown and remain subject of future studies.
Materials and Methods
Ethics Statement
The study was approved by the Animal Care and Use
Committee of the state of Hesse (Regierungspra ¨sidium Darm-
stadt), Darmstadt, Germany (V54-19c20/15-F91/56). Surgery
and animal care was performed in accordance with the ‘‘Guide for
the care and use of laboratory animals’’ (National Institutes of
Health, volume 25, no. 28, revised 1996), EU Directive 86/
609 EEC and German Protection of Animals Act.
Deguelin Preparation and Administration
The HIF-1 inhibitor Deguelin was obtained from Enzo Life
Sciences (Lo ¨rrach, Germany). Stock solution was prepared by
dissolving Deguelin in 100% DMSO at 25 mg/ml and stored at
220uC until further use. For the use in animals, Deguelin was
dissolved in corn oil at a final concentration of 10 mg/ml.
Deguelin was applied via gavage twice a day at a dose of 4 mg/kg
BW. Treatment started 3 days before transplantation in donors
and recipients and ended 48 hours after transplantation (in
recipients) (Fig. 10).
Microvascular and Lung Epithelial Cell Hypoxia Assay
Human microvascular endothelial cells (HMECs) and human
lung epithelial derived cells (HTB-177) (ATCC, Wesel, Germany)
were cultured in 6 well plates (10e5 cells/well) to 80–90%
confluence, using RPMI 1640 medium (PAA Laboratories,
Pasching, Austria) plus 10% FCS. For the hypoxia assay, the
medium was equilibrated at 37uC in 2% O2 and 5% CO2 for
24 h. 12 hours prior to onset of hypoxia, 100 nM final
concentration of Deguelin was added to the cells. After 6 h of
hypoxia (37uC, 2%O2, 5% CO2), cells were harvested and
proteins were isolated. Experiments were performed in triplicate.
Animals
Male Sprague Dawley rats (SD, Janvier, St. Berthevin, France)
weighing 225–250 g were housed in the central research
establishment of the Goethe-University Frankfurt. At the begin-
ning of the experiment, rats were randomized to form pairs of
donor and recipient rats, which were kept together in approved
plastic cages (2 animals per cage), had water and food ad libitum
and were housed in rooms equipped with a 12 h light cycle. The
rats were individualized using a unique color code printed on the
tail with water-resistant paint.
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In general the experiment was divided into two stages. The first
stage comprised harvesting lungs from animals either treated or
not treated with Deguelin under different ischemic conditions
(Table 1).
To harvest the lungs the rats were anesthetized with Ketamin-
Xylazine (75/10 mg/kg body weight) and intubated. Anesthesia
was continued with Isoflurane (1.5 vol %) using a pressure
controlled small animal ventilator (Fo ¨hr Medical Instruments,
Seeheim-Ober Beerbach, Germany) at 85 bpm and pmax=25 m-
bar. Before removal, the lungs were flushed with 20 mL perfusion
solution (PerfadexH solution, kept at 4uC) until the lungs turned
Figure 9. Specificity of Deguelin. Western blot analysis of total AKT (tAKT), phospho AKT (pAKT) and ACTB of transplanted lungs derived from
animals that were either treated with Deguelin or without (control). However a trend to lower levels of pAKT (n.s.; P=0.2403) may be seen, no
significant differences are observed between the two groups, underlining HIF-1 downregulating potency of Deguelin.
doi:10.1371/journal.pone.0039265.g009
Figure 10. Therapeutic schedule. Scheme representing the therapy
(gavages) and transplantation schedule. The lightning marks the day of
transplantation. Experiment ends 48 hours after transplantation.
doi:10.1371/journal.pone.0039265.g010
Table 1. Layout of the first experimental stage.
Group Size Treatment Ischemic conditions
n=6 Deguelin for 3 days warm ischemia for 1 h
n=6 untreated warm ischemia for 1 h
n=6 untreated no ischemia (sham)
doi:10.1371/journal.pone.0039265.t001
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complex, one half of the obtained organs were snap-frozen in
liquid nitrogen, the other half was stored in 4% formaldehyde. In
the second stage of the experiments, an orthotopic allo-isogenic
(SD-SD) unilateral lung transplantation was performed. These
transplantation experiments compromised 2 groups: Deguelin-
treated animals vs. control animals without treatment (Table 2,
Fig. 10).
Donor Procedure
Donor animals were anesthetized, intubated and ventilated as
described earlier. Donor organs were obtained after perfusion of
the heart-lung complex using an antegrade perfusion via the
pulmonary artery. Lungs from the Deguelin group and control
lungs were perfused each with 20 ml of PerfadexH (Vitrolife,
Kungsbacka, Sweden), a solution with low potassium, not
exceeding 20 cm H
2O hydrostatic pressure. After removal, the
heart-lung complex was wrapped in sterile gauze and kept on ice
until backtable preparation.
Backtable
For this purpose the left lung artery, vein and bronchus were
dissected under sterile conditions from enclosing tissue. The loose
ends of the three structures were drawn through cuffs (made from
venous catheter), everted and fixed using a 6–0 prolene thread.
The prepared left lung grafts were wrapped in sterile gauze and
stored on ice until transplantation.
Recipient Procedure
The recipient rats were anesthetized as described before. The
thoracic cavern was opened using a left antero-lateral thoracot-
omy. The left lung lobe was carefully prepared, exposing the
pulmonary artery, vein and bronchus. Then, the vessels and
bronchus were selectively ligated using 6–0 prolene vessel loops to
obstruct air and blood flow. Artery and vein were incised and
flushed with a solution of Heparin/saline (150 U/mL). Then the
bronchus was incised and the prepared donor lung was placed on
top of the recipients left lung lobe. Connections between the
structures of the donor organ and the recipient organism were
established by inserting the corresponding donor structures into
the incisions of the recipient vessels and bronchus. The generated
connections were secured using 5–0 silk ligation (Fig. 11). The
reperfusion of the vein and artery and the reestablishment of
airflow through the bronchus was accomplished in the order
mentioned. After successful transplantation the recipient’s left lung
lobe was removed, the donor organ was placed into the thorax and
the wound was closed. After successful suturing, local anesthesia
was instilled (Ropivacain 0,2%, 1 ml) to ensure post-operative pain
relief. Enrofloxacin was used as a post-surgical antibiotic and pain
was controlled with Piritramid administered via drinking water
(1,5 mg/50 ml). The recipient rats were observed for an additional
48 h and then killed under deep anesthesia. The Lungs were
harvested, dissected and stored as described earlier.
Wet-to-dry Ratio
A small part of the collected lungs was minced and stored in a
reaction tube and the weight was determined. Then the tube was
placed in an oven at 60uC for 72 h. Thereafter, the tube was re-
weighed and the ratio between wet and dry weight was calculated.
Comparison of the wet-to-dry ratios of different organ samples
allowed drawing conclusions regarding the dimension of lung
edema as reported elsewhere [22].
RNA Isolation and PCR
RNA was isolated from homogenized lung samples using
TriReagent solution (Sigma-Aldrich, USA) according to the
manufacturer’s protocol. cDNA was synthesized using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, USA). Realtime-PCR
was performed using the StepOne Plus Realtime PCR (Applied
Biosystems, USA) and following oligonucleotides: rCXCR4 forw.
CACCAACAGCCAGAGCGCGA, rev. TGCGCTTCTGG-
TGGCCCTTG; rVEGF-A forw. CCAGGCTGCACCCACGA-
CAG, rev.:CGCACACCGCCATTAGGGGCA; rICAM-1 forw.
CGCAGTCCTCGGCTTCTGCC, rev. CGCAGTCCTCGGC-
TTCTGCC; rACTB forw. CTTGCAGCTCCTCCGTCGCC,
rev. CTTGCTCTGGGCCTCGTCGC; rVCAM-1 forw. GG-
TGGCTGCACAGGTTGGGG, rev. ACCCACAGGGCTCAG-
CGTCA; rCD 163 forw. TGGGATCGCCGTGACGCTTC,
rev. CAGCGACTGCCTCCACCGAC; rIL4 forw. GGCTTC-
CAGGGTGCTTCGCAA, rev. GTGGACTCATTCACGGTG-
CAGC; rCCL2 forw. GAGGCCAGCCCAGAAACCAGC, rev.
GCAGCAGGTGAGTGGGGCATT.
Protein Isolation, Western Blot and ELISA
Briefly, protein from left lungs was isolated as described earlier
[23,62]. 10% and 7.5% SDS-gels were loaded with 50 mg protein.
Proteins were immunodetected on Hybond C supermembrane
(Amersham Pharmacia Biotech, Buckinghamshire) with Spectra
broad range marker (Fermentas, Germany) as a standard. The
blots were probed with antibodies as follows: HIF-1 alpha - mouse
monoclonal antibody (Abcam, Cambridge, UK), VEGF - mouse
monoclonal antibody (Abcam, Cambridge, UK). Digitalization
and evaluation of the blots was performed with a Kodak Imager
(Carestream, Stuttgart, Germany). For serum sampling, blood was
withdrawn and clotting was performed for 15 minutes followed by
centrifugation with 3000 RPM for 10 minutes at 4uC. Serum
supernatant was transferred to a new tube and then stored at
280uC for further processing. ELISA on rat IL6 and rat
Interferon-c (Thermo Fisher, Braunschweig, Germany) were
performed according to the manufacturer’s protocol. Detection
of the concentration was performed using a microplate reader
(Bio-Tek Instruments, Bad Friedrichshall, Germany).
Histology and Immunohistochemistry
One half of the samples from the left lung lobe was fixed in
formaldehyde 4% for 48 h and dehydrated afterwards in solutions
Table 2. Layout of the second experimental stage.
Group Size Treatment Animal
n=6 Deguelin for 3 days preoperative donor
Deguelin for 3 days preoperative +2 days postoperative recipient
n=12 Untreated controls (donor + recipient)
doi:10.1371/journal.pone.0039265.t002
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39265Figure 11. Technique of lung transplantation. (A) For perfusion, a venous catheter is placed through an incision in the right ventricle into the
pulmonary artery. After perfusion, the heart-lung complex is removed in toto, suspended on the trachea that is ligated in maximal inspiration to avoid
atelectasis. B) Cuffs are prepared using venous catheters. The vessel is slipped through the lumen and fixed with a 6–0 polypropylene suture. C)
Donor (cuffed) blood vessels and bronchus were slipped (sleeved) into the recipient’s artery, bronchus and vein. When no twisting of the
corresponding structure was observed, the anastomosis was secured with a 5–0 Silk suture placed around the cuff and sleeved recipient’s structure.
doi:10.1371/journal.pone.0039265.g011
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benzoate-I for 16 h and methylbenzoate-II for 8 h. After washing
in liquid Paraffin (Merck, Darmstadt, Germany) samples were
embedded in paraffin and cut to 4 mm slides. Samples were stained
with haematoxylin and eosin (AppliChem, Darmstadt, Germany)
according to the manufacturer’s protocol. Immunohistochemistry
was performed with DAB-staining, using RM-4 pan-macrophage/
dendritic cell marker (TransGenic Inc., Kobe, Japan), CD 163
(AbD Serotec, Du ¨sseldorf, Germany), CD 68 (Millipore, Schwal-
bach, Germany), ICAM-1 (Labomics, Nivelles, Belgium) and
CXCR4 (Abcam, Cambridge, UK) antibodies [62]. Briefly, after
deparaffinization, the slides were rehydrated in decreasing alcohol
concentrations. After blocking with 6% serum (from the species of
the secondary antibody), the primary antibody was incubated for
2 h at room temperature. For detection, a secondary antibody
labelled with HRP (anti mouse IgG, DAKO, Hamburg, Germany)
(for CD 163, CD 68 and ICAM-1) was incubated for 1 h at room
temperature. For detection of CXCR4 a biotinylated anti rabbit
antibody was incubated for 1 h prior to detection with
streptavidin-HRP (AXXORA, Lo ¨rrach, Germany). Development
was performed with DAB incubation for 10 minutes and
counterstaining was done with haematoxylin for 10 min. Images
were taken with the Leica DM5000B microscope and analyzed
using an automatized MatLab algorithm. The software determines
the number of pixel in each RGB channel, thus measuring the
relative area occupied by positive staining per image. Quantifica-
tion was done setting brown pixels proportioned to total number of
pixel.
Statistical Analysis
Statistical analysis was performed with GraphPad PrismH 5.02
software (GraphPad Software, Inc., San Diego, California).
Results are expressed as means 6 standard error of the mean
(SEM). Statistical significance was calculated using one-way
ANOVA followed by Student’s t test. Statistical significance was
set to p,0.05.
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